COLLEGIUM PHARMACEUTICAL INC

COLLNASDAQ

🏆 #2114 by market capEarnings Nov 5US Equity

$25.98▼ $1.17 (−4.49%)

🌙 After hours$26.38▲ 1.56%Regular close · extended-hours price shown

1h—

24h▼ 4.5%

7d▼ 27.3%

14d▼ 28.4%

30d▼ 25.4%

1y▼ 31.4%

🏦Market Cap

$843M

Small Cap

📈Revenue Growth (YoY)

+23.6%

Healthy

📊Gross Margin

60.0%

High

💵FCF Margin

40.6%

Strong

⚖️P/S Ratio

1.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $25.58 – $26.20
52-Week Range: $25.90 – $50.79
Volume: $2.43B
Avg Volume: $2.82B
Shares Outstanding: 32.4M
Next Earnings: Oct 23, 2026

Fundamentals Snapshot

Annual Revenue: $781M
Last Q Revenue: $200M
P/E Ratio: 17.0
P/S Ratio: 1.0x
EPS (TTM): $1.48
Dividend Yield: 0.00%

Why Investors Own COLL

✓High-growth profile — revenue up +12.2% YoY with expanding US Equity exposure.
✓Healthy economics — 58% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$781M▲ +8.3% YoY

Gross Margin (TTM)

57.9%▲ +2.3% YoY

Operating Income (TTM)

$240M▲ +8.3% YoY

Free Cash Flow (TTM)

$152M▲ +8.3% YoY

About COLLEGIUM PHARMACEUTICAL INC

Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.

🦦